Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Cetta

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The Journal of Headache and Pain|November 24, 2022
Tracking the evolution of non-headache symptoms through the migraine attackRoberta Messina, Ilaria Cetta, Bruno Colombo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 27, 2020
Stress in paediatric migraine: a trigger factor?Bruno Colombo, Ilaria Cetta, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 6, 2022
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal studyIlaria Cetta, Roberta Messina, Laura Zanandrea, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 23, 2021
Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case reportAntonino Giordano, Ilaria Cetta, Mario Orrico, et al.
Expert Review of Neurotherapeutics|June 20, 2026
An update on the differential diagnosis of migraine in adults: when and how neuroimaging makes the differenceRoberta Messina, Alessandro Antoniazzi, Ilaria Cetta, et al.
Multiple Sclerosis and Related Disorders|November 13, 2019
Cortical M1 plasticity and metaplasticity in patients with multiple sclerosisViola Baione, Daniele Belvisi, Antonio Cortese, et al.
Journal of Neurology|October 28, 2025
Clinical and neuroradiological evolution of thymoma-associated anti-GABAA receptor autoimmune encephalitis: insights from a clinical case reportLeonardo Palazzo, Ilaria Cetta, Lucia Bongiovanni, et al.
European Journal of Neurology|September 5, 2024
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real-life studyLaura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology|May 25, 2023
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experienceSimone Guerrieri, Chiara Bucca, Agostino Nozzolillo, et al.
The Journal of Headache and Pain|June 7, 2022
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The Journal of Headache and Pain|November 24, 2022
Tracking the evolution of non-headache symptoms through the migraine attackRoberta Messina, Ilaria Cetta, Bruno Colombo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 27, 2020
Stress in paediatric migraine: a trigger factor?Bruno Colombo, Ilaria Cetta, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 6, 2022
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal studyIlaria Cetta, Roberta Messina, Laura Zanandrea, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 23, 2021
Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case reportAntonino Giordano, Ilaria Cetta, Mario Orrico, et al.
Expert Review of Neurotherapeutics|June 20, 2026
An update on the differential diagnosis of migraine in adults: when and how neuroimaging makes the differenceRoberta Messina, Alessandro Antoniazzi, Ilaria Cetta, et al.
Multiple Sclerosis and Related Disorders|November 13, 2019
Cortical M1 plasticity and metaplasticity in patients with multiple sclerosisViola Baione, Daniele Belvisi, Antonio Cortese, et al.
Journal of Neurology|October 28, 2025
Clinical and neuroradiological evolution of thymoma-associated anti-GABAA receptor autoimmune encephalitis: insights from a clinical case reportLeonardo Palazzo, Ilaria Cetta, Lucia Bongiovanni, et al.
European Journal of Neurology|September 5, 2024
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real-life studyLaura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology|May 25, 2023
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experienceSimone Guerrieri, Chiara Bucca, Agostino Nozzolillo, et al.
The Journal of Headache and Pain|June 7, 2022
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Pageof 2